Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

The purpose of this study is to follow patients from the feeder studies who have achieved
SVR24 to assess durability of SVR24, and to assess the changes in liver disease, development
of hepatocellular carcinoma and post-treatment safety over time.

Inclusion Criteria:

1. Males or females aged ≥18

2. Have previously completed a Novartis-sponsored hepatitis C study and received
alisporivir

3. Have achieved SVR24

Exclusion Criteria:

1. Use of any investigational drugs within 5 half-lives of enrollment, or within 30 days
of that medication, whichever is longer.

2. Use or planned use to start a new course of hepatitis C therapy